Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 1/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 7/20 | 0.40 |
| ▸ | APAF1 | O14727 | 2/20 | 0.40 |
| ▸ | LMNA | P02545 | 2/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | APEX1 | P27695 | 1/20 | 0.40 |
| ▸ | PLCG1 | P19174 | 1/20 | 0.40 |
| ▸ | ABCC2 | Q92887 | 1/20 | 0.40 |
| ▸ | SIRT5 | Q9NXA8 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 6/20 | 0.40 |
| ▸ | CTDSP1 | Q9GZU7 | 2/20 | 0.40 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.40 |
| ▸ | CNR1 | P21554 | 1/20 | 0.40 |
| ▸ | PSMD14 | O00487 | 1/20 | 0.40 |
| ▸ | MMP2 | P08253 | 1/20 | 0.40 |
| ▸ | NR1I2 | O75469 | 3/20 | 0.38 |
| ▸ | ESR1 | P03372 | 1/20 | 0.38 |
| ▸ | PGR | P06401 | 1/20 | 0.38 |
| ▸ | PPARG | P37231 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2595984 | 1.00 | KCNH2 (0.43) | KCNH2TDP1APAF1LMNATSHR | |
| SCHEMBL14773851 | 1.00 | KCNH2 (0.43) | KCNH2TDP1APAF1LMNATSHR | |
| SCHEMBL17188207 | 0.95 | TDP1 (0.47) | KCNH2TDP1APAF1LMNATSHR | |
| SCHEMBL16181564 | 0.91 | HSD17B10 (0.46) | KCNH2TDP1LMNAPLCG1L3MBTL1 | |
| SCHEMBL2595314 | 0.90 | KCNH2 (0.44) | KCNH2TDP1APAF1LMNATSHR | |
| SCHEMBL2595316 | 0.90 | KCNH2 (0.44) | KCNH2TDP1APAF1LMNATSHR | |
| SCHEMBL14773850 | 0.90 | KCNH2 (0.44) | KCNH2TDP1APAF1LMNATSHR | |
| SCHEMBL14959767 | 0.89 | KCNH2 (0.35) | KCNH2TDP1APAF1LMNATSHR | |
| SCHEMBL12334104 | 0.89 | KCNH2 (0.35) | KCNH2TDP1APAF1LMNATSHR | |
| SCHEMBL12306316 | 0.89 | KCNH2 (0.35) | KCNH2TDP1APAF1LMNATSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9163034-B2 | Crystalline (6R,7R)-7-{2-(5-amino-[1,2,4] thiadiazol-3-yl)-2-[(Z)-trityloxyimino]-acetylamino}-3-[(R)-1′-tert-butoxycarbonyl-2-oxo-[1,3′]bipyrrolidinyl-(3E)-ylidenemethyl]-8-oxo-5-thia-1-aza-bicyclo[4.2.0]oct-2-ene-2-carboxylic acid benzhydryl ester; its manufacture and use | BASILEA PHARMACEUTICA AG (CH) | 2015-10-20 | — | — | US | claimed |
| US-20150005491-A1 | CRYSTALLINE (6R,7R)-7--3- [(R)-1'-TERT-BUTOXYCARBONYL-2-OXO-[1,3']BIPYRROLIDINYL-(3E)-YLIDENEMETHYL]-8-OXO-5-THIA-1-AZA-BICYCLO[4.2.0] OCT-2-ENE-2-CARBOXYLIC ACID BENZHYDRYL ESTER; ITS MANUFACTURE AND USE | BASILEA PHARMACEUTICA AG (CH) | 2015-01-01 | — | — | US | claimed |
| EP-2268648-B1 | Crystalline (6R,7R)-7-{2-(5-Amino-[1,2,4]thiadiazol-3-yl)-2-[(Z)-trityloxyimino]-acetylamino}-3-[(R)-1'-tert- butoxycarbonyl-2-oxo-[1,3]bipyrrolidinyl-(3E)-ylidenemethyl]-8-oxo-5-thia-1-aza-bicyclo[4.2.0]oct-2-ene-2-carboxylic acid benzhydryl ester; its manufacture and use | BASILEA PHARMACEUTICA AG (CH) | 2012-05-16 | — | — | EP | claimed |
| US-20110137026-A1 | Crystalline (6r,7r)-7--3- [(R)-1'-Tert-Butoxycarbonyl-2-Oxo-[1,3']Bipyrrolidinyl-(3e)-Ylidenemethyl]-8-Oxo-5-Thia-1-Aza-Bicyclo[4.2.0] Oct-2-Ene-2-Carboxylic Acid Benzhydryl Ester; Its Manufacture and Use | BASILEA PHARMACEUTICA AG (CH) | 2011-06-09 | — | — | US | claimed |
| US-9499566-B2 | Oxidation process for preparing 3-formyl-cephem derivatives | Basilea Pharmaceutica International (CH) | 2016-11-22 | — | — | US | disclosed |
| US-9163034-B2 | Crystalline (6R,7R)-7-{2-(5-amino-[1,2,4] thiadiazol-3-yl)-2-[(Z)-trityloxyimino]-acetylamino}-3-[(R)-1′-tert-butoxycarbonyl-2-oxo-[1,3′]bipyrrolidinyl-(3E)-ylidenemethyl]-8-oxo-5-thia-1-aza-bicyclo[4.2.0]oct-2-ene-2-carboxylic acid benzhydryl ester; its manufacture and use | BASILEA PHARMACEUTICA AG (CH) | 2015-10-20 | — | — | US | disclosed |
| US-20150218189-A1 | Oxidation Process For Preparing 3-Formyl-Cephem Derivatives | BASILEA PHARMACEUTICA AG | 2015-08-06 | — | — | US | disclosed |
| US-9006422-B2 | Oxidation process for preparing 3-formyl-cephem derivatives | BASILEA PHARMACEUTICA INTERNATIONAL LTD. (CH) | 2015-04-14 | — | — | US | disclosed |
| EP-2569321-B1 | OXIDATION PROCESS FOR PREPARING 3-FORMYL-CEPHEM DERIVATIVES | BASILEA PHARMACEUTICA INTERNAT LTD (CH) | 2015-03-04 | — | — | EP | disclosed |
| US-20150005491-A1 | CRYSTALLINE (6R,7R)-7--3- [(R)-1'-TERT-BUTOXYCARBONYL-2-OXO-[1,3']BIPYRROLIDINYL-(3E)-YLIDENEMETHYL]-8-OXO-5-THIA-1-AZA-BICYCLO[4.2.0] OCT-2-ENE-2-CARBOXYLIC ACID BENZHYDRYL ESTER; ITS MANUFACTURE AND USE | BASILEA PHARMACEUTICA AG (CH) | 2015-01-01 | — | — | US | disclosed |
| US-8865697-B2 | Crystalline (6R,7R)-7-{2-(5-amino-[1,2,4] thiadiazol-3-yl)-2-[(Z)-trityloxyimino]-acetylamino}-3-[(R)-1′-tert-butoxycarbonyl-2-oxo-[1,3′]bipyrrolidinyl-(3E)-ylidenemethyl]-8-oxo-5-thia-1-aza-bicyclo[4.2.0]oct-2-ene-2-carboxylic acid benzhydryl ester; its manufacture and use | BASILEA PHARMACEUTICA AG (CH) | 2014-10-21 | — | — | US | disclosed |
| EP-2569321-A1 | OXIDATION PROCESS FOR PREPARING 3-FORMYL-CEPHEM DERIVATIVES | Basilea Pharmaceutica International Ltd. (CH) | 2013-03-20 | — | — | EP | disclosed |
| US-20110137026-A1 | Crystalline (6r,7r)-7--3- [(R)-1'-Tert-Butoxycarbonyl-2-Oxo-[1,3']Bipyrrolidinyl-(3e)-Ylidenemethyl]-8-Oxo-5-Thia-1-Aza-Bicyclo[4.2.0] Oct-2-Ene-2-Carboxylic Acid Benzhydryl Ester; Its Manufacture and Use | BASILEA PHARMACEUTICA AG (CH) | 2011-06-09 | — | — | US | disclosed |
| EP-1435357-B1 | New process for the preparation of vinyl-pyrrolidinone cephalosporine derivatives | BASILEA PHARMACEUTICA AG (CH) | 2010-03-17 | — | — | EP | disclosed |
| EP-1289998-B1 | NEW PROCESS FOR THE PREPARATION OF VINYL-PYRROLIDINONE CEPHALOSPORINE DERIVATIVES | BASILEA PHARMACEUTICA AG (CH) | 2005-03-30 | — | — | EP | disclosed |
| EP-1435357-A2 | New process for the preparation of vinyl-pyrrolidinone cephalosporine derivatives | Basilea Pharmaceutica AG (CH) | 2004-07-07 | — | — | EP | disclosed |
| EP-1289998-A1 | NEW PROCESS FOR THE PREPARATION OF VINYL-PYRROLIDINONE CEPHALOSPORINE DERIVATIVES | Basilea Pharmaceutica AG (CH) | 2003-03-12 | — | — | EP | disclosed |
| US-6504025-B2 | In fewer steps and is obtained in higher yield; chemical intermediates; useful in treating methicillin resistent Staphylococcus aureus and Pseudomonas aeruginosa | BASILEA PHARMACEUTICA AG (CH) | 2003-01-07 | — | — | US | disclosed |
| US-20020019381-A1 | Process for the preparation of vinyl-pyrrolidinone cephalosporin derivatives | BASILEA PHARMACEUTICA AG (CH) | 2002-02-14 | — | — | US | disclosed |
| WO-2001090111-A1 | NEW PROCESS FOR THE PREPARATION OF VINYL-PYRROLIDINONE CEPHALOSPORINE DERIVATIVES | BASILEA PHARMACEUTICA AG (CH) | 2001-11-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150005491-A1 | CRYSTALLINE (6R,7R)-7--3- [(R)-1'-TERT-BUTOXYCARBONYL-2-OXO-[1,3']BIPYRROLIDINYL-(3E)-YLIDENEMETHYL]-8-OXO-5-THIA-1-AZA-BICYCLO[4.2.0] OCT-2-ENE-2-CARBOXYLIC ACID BENZHYDRYL ESTER; ITS MANUFACTURE AND USE | MED1, MED16, CYP2D6 | KCNH2 3168/4885TDP1 1147/4885APAF1 4125/4885 |
| US-20150218189-A1 | Oxidation Process For Preparing 3-Formyl-Cephem Derivatives | MAOB, TET2, TET1 | KCNH2 987/4885TDP1 1481/4885APAF1 3359/4885 |
| US-20020019381-A1 | Process for the preparation of vinyl-pyrrolidinone cephalosporin derivatives | DHPS, PEPD, VAT1 | KCNH2 2122/4885TDP1 3016/4885APAF1 3266/4885 |
| US-20110137026-A1 | Crystalline (6r,7r)-7--3- [(R)-1'-Tert-Butoxycarbonyl-2-Oxo-[1,3']Bipyrrolidinyl-(3e)-Ylidenemethyl]-8-Oxo-5-Thia-1-Aza-Bicyclo[4.2.0] Oct-2-Ene-2-Carboxylic Acid Benzhydryl Ester; Its Manufacture and Use | MED1, MED16, CYP2D6 | KCNH2 3168/4885TDP1 1147/4885APAF1 4125/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.